Profile data is unavailable for this security.
About the company
Venture Life Group PLC is a United Kingdom-based consumer self-care company. The principal activities of the Company are the development, manufacturing, and commercialization of healthcare products, including medical devices, food supplements and cosmetics for the ageing population. The Company's product portfolio includes products, such as the UltraDEX and Dentyl oral care product ranges; the Balance Activ range in the area of women's intimate healthcare; the Lift Glucose and Glucogel product ranges for hypoglycaemia; Gelclair, Xonrid, and Pomi-T for oncology support products provide symptomatic relief for some of the side effects associated with cancer and its treatment; the Procto-eze Plus product ranges for hemorrhoids, and other Dermatology products. The Company operates through two segments: Venture Life Brands and Customer Brands. The Company's subsidiaries include Venture Life Limited, Lubatti Limited, Periproducts Limited, HL Healthcare Ltd, and Venture Life Healthcare Ltd.
- Revenue in GBP (TTM)51.41m
- Net income in GBP921.00k
- Incorporated2005
- Employees165.00
- LocationVenture Life Group PLCUnit 12, The Courtyard, Eastern RoadBRACKNELL RG12 2XBUnited KingdomGBR
- Phone+44 134 457 8004
- Fax+44 134 474 2970
- Websitehttps://www.venture-life.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sareum Holdings Plc | 0.00 | -4.26m | 27.24m | 5.00 | -- | 42.97 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
| Science in Sport PLC | 65.93m | -7.07m | 28.71m | 158.00 | -- | 0.7213 | -- | 0.4354 | -0.0464 | -0.0464 | 0.4239 | 0.2184 | 0.8479 | 4.20 | 3.83 | 417,278.50 | -9.09 | -9.69 | -13.75 | -11.97 | 41.88 | 47.09 | -10.72 | -11.94 | 0.6921 | -2.31 | 0.2825 | -- | 1.97 | 32.50 | -96.47 | -- | 49.81 | -- |
| CRUSHMETRIC Group Ltd | 398.34k | -879.48k | 30.00m | 20.00 | -- | 1.18 | -- | 75.30 | -0.0072 | -0.0072 | 0.0028 | 0.1062 | 0.0255 | 7.14 | 2.64 | 19,917.22 | -5.72 | -40.65 | -8.35 | -- | 34.66 | 37.39 | -224.56 | -140.54 | 0.072 | -14.42 | 0.0558 | -- | 119.19 | -1.40 | -7.26 | -- | 12.11 | -- |
| Arecor Therapeutics PLC | 3.38m | -9.42m | 41.81m | 51.00 | -- | 3.16 | -- | 12.37 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
| Venture Life Group PLC | 51.41m | 921.00k | 51.55m | 165.00 | 76.45 | 0.676 | 6.37 | 1.00 | 0.0053 | 0.0053 | 0.3847 | 0.6028 | 0.42 | 2.80 | 3.15 | 311,575.80 | 0.7525 | 1.58 | 0.9274 | 1.83 | 39.19 | 40.14 | 1.79 | 3.99 | 0.7355 | 2.12 | 0.2424 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
| Celadon Pharmaceuticals PLC | 20.74k | -8.06m | 65.17m | -- | -- | 20.79 | -- | 3,142.34 | -0.1306 | -0.1306 | 0.0003 | 0.0488 | 0.0016 | 267.85 | 0.0248 | -- | -64.68 | -- | -71.16 | -- | -29,080.42 | -- | -40,384.18 | -- | 1.84 | -12.45 | 0.6052 | -- | -- | -- | -- | -- | -- | -- |
| Poolbeg Pharma PLC | 0.00 | -3.93m | 68.00m | 12.00 | -- | 4.71 | -- | -- | -0.0079 | -0.0079 | 0.00 | 0.0289 | 0.00 | -- | -- | -- | -22.65 | -- | -24.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.11 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Slater Investments Ltd.as of 11 Jan 2024 | 22.77m | 18.00% |
| BGF Investment Management Ltd.as of 16 Feb 2024 | 11.40m | 9.01% |
| Hargreaves Lansdown Asset Management Ltd.as of 31 Dec 2023 | 10.60m | 8.38% |
| River Global Investors LLPas of 31 Dec 2023 | 9.85m | 7.79% |
| Close Asset Management Ltd.as of 31 Dec 2023 | 9.35m | 7.39% |
| Stonehage Fleming Investment Management Ltd.as of 31 Dec 2023 | 8.49m | 6.71% |
| Chelverton Asset Management Ltd.as of 31 Dec 2023 | 7.03m | 5.56% |
| Octopus Investments Ltd.as of 20 May 2022 | 3.29m | 2.60% |
| Quilter Cheviot Ltd.as of 02 Nov 2023 | 1.42m | 1.12% |
| J. M. Finn & Co. Ltd.as of 02 Nov 2023 | 1.31m | 1.03% |
